A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Prexasertib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 12 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 22 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.